The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Alendronate Decreases Hip Fracture Risk in Older Patients Using Oral Prednisolone

Alendronate Decreases Hip Fracture Risk in Older Patients Using Oral Prednisolone

August 21, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients age 65 years or older who use medium to high doses of prednisolone and receive treatment with alendronate experience significantly lower risk of hip fracture over a median of 1.32 years than patients on prednisolone who are not treated with alendronate. Kristian F. Axelsson, MD, MSc, from Skaraborg Hospital in Sweden, and colleagues published the results of their observational study in the July 11 issue of JAMA. Their findings support the use of alendronate in older patients taking prednisolone.1

You Might Also Like
  • Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World
  • Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids
  • After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk
Also By This Author
  • POP1-Based Treatments May Reduce Inflammation

The researchers used a Swedish national database of 433,195 patients and compared patients on prednisolone to patients not on prednisolone. They found that the risk of hip fracture only increased among patients taking ≥5 mg prednisolone daily and, thus, focused their efforts on these patients. For their retrospective cohort study, researchers identified 1,802 patients who were prescribed alendronate after at least three months of oral prednisolone treatment. These patients had a mean age of 79.9 years and had been receiving alendronate for a median duration of 2.9 years. The majority of patients were women (70%). The investigators used propensity score matching to create a well-matched group of patients taking prednisolone who were not treated with alendronate. The standardized difference between the two groups was below 10% for all baseline characteristics—except for osteoporosis, which was 12.4%.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators note that the number of hip fractures in their study was small: 27 in the alendronate-treated group and 73 in the no-alendronate group. This number corresponded to incidence rates of 9.5 (95% confidence interval [CI], 6.5–13.9) fractures per 1,000 person-years in the alendronate group and 27.2 (95% CI, 21.6–34.2) fractures per 1,000 person-years in the no-alendronate group. When researchers used an unadjusted Cox model, alendronate treatment was associated with a lower risk of hip fracture (hazard ratio [HR] 0.35; 95% CI, 0.23–0.55). Researchers then used a multivariable-adjusted Cox model, adjusting for anthropometric variables, clinical risk factors and comorbidity, and calculated that the use of alendronate was associated with a lower risk of hip fracture (HR 0.35; 95% CI, 0.22–0.54). When they included cumulative prednisolone dose as a covariate in the multivariable Cox model, the risk estimate for the association between alendronate use and risk of hip fracture did not change. They also performed extensive sensitivity analyses with several alendronate treatment variables to address possible sources of bias and were unable to identify any.

Additionally, the researchers documented 642 deaths (35.6%) among patients using alendronate and 698 deaths (38.7%) among those not using alendronate. When they used a Cox model adjusted for age, sex, height, weight and Charlson comorbidity index, they found that alendronate treatment in patients using prednisolone was associated with a lower risk of death (HR 0.88; 95% CI, 0.79–0.98) when compared with patients not treated with alendronate. Moreover, deaths for which hip fractures were listed as a possible cause did not differ significantly between the two groups. Incident fall injuries also did not differ significantly between alendronate-treated and untreated patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: alendronate, elderly, Fractures, hip fracture, hip fracture risk, prednisolone

You Might Also Like:
  • Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World
  • Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids
  • After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk
  • Sequential Therapy May Reduce Hip Fracture Risk; Plus New Biosimilar Available in Canada

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)